This research develops a method to deliver EGCG, a green tea compound known to break apart Alzheimer's-related protein tangles, into the brain. By chemically attaching EGCG to a carrier that can cross the brain's protective barrier, the project aims to create a potential therapeutic strategy for slowing memory loss and disease progression.

My research investigates AU403, a novel LXR agonist, as a potential treatment for frontotemporal dementia. Using mouse brain slice models, the study shows that AU403 restores damaged myelin, improves neuronal communication, and reverses disease-like symptoms, offering hope for a condition with no approved therapies.

The researcher rebuilds how cells sort materials to understand Alzheimer’s and Parkinson’s diseases. Using proteins and lipids like Lego pieces, they study how a key protein, retromer, malfunctions and disrupts cell transport. With cryogenic electron tomography, they aim to model this process and guide new treatments that restore healthy cellular function.